JP2022527054A - 吸入可能な乾燥粉末 - Google Patents

吸入可能な乾燥粉末 Download PDF

Info

Publication number
JP2022527054A
JP2022527054A JP2021556771A JP2021556771A JP2022527054A JP 2022527054 A JP2022527054 A JP 2022527054A JP 2021556771 A JP2021556771 A JP 2021556771A JP 2021556771 A JP2021556771 A JP 2021556771A JP 2022527054 A JP2022527054 A JP 2022527054A
Authority
JP
Japan
Prior art keywords
dry powder
inhaler
particles
pharmaceutical composition
diketopiperazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021556771A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527054A5 (https=
Inventor
ジェイ.グアルネリ ジョセフ
シー.スマットニー チャド
Original Assignee
マンカインド コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マンカインド コーポレイション filed Critical マンカインド コーポレイション
Publication of JP2022527054A publication Critical patent/JP2022527054A/ja
Publication of JP2022527054A5 publication Critical patent/JP2022527054A5/ja
Priority to JP2025002002A priority Critical patent/JP2025061049A/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021556771A 2019-03-22 2020-03-20 吸入可能な乾燥粉末 Pending JP2022527054A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025002002A JP2025061049A (ja) 2019-03-22 2025-01-06 吸入可能な乾燥粉末

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962822303P 2019-03-22 2019-03-22
US62/822,303 2019-03-22
PCT/US2020/023977 WO2020198051A1 (en) 2019-03-22 2020-03-20 Inhalable dry powders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025002002A Division JP2025061049A (ja) 2019-03-22 2025-01-06 吸入可能な乾燥粉末

Publications (2)

Publication Number Publication Date
JP2022527054A true JP2022527054A (ja) 2022-05-30
JP2022527054A5 JP2022527054A5 (https=) 2024-06-04

Family

ID=72608595

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021556771A Pending JP2022527054A (ja) 2019-03-22 2020-03-20 吸入可能な乾燥粉末
JP2025002002A Pending JP2025061049A (ja) 2019-03-22 2025-01-06 吸入可能な乾燥粉末

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025002002A Pending JP2025061049A (ja) 2019-03-22 2025-01-06 吸入可能な乾燥粉末

Country Status (6)

Country Link
US (1) US20220241271A1 (https=)
EP (1) EP3941438A4 (https=)
JP (2) JP2022527054A (https=)
CA (1) CA3133804A1 (https=)
MX (2) MX2021011491A (https=)
WO (1) WO2020198051A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3171220A1 (en) * 2020-03-19 2021-09-23 Glenn MATTES Dried particle inhalation for delivery of cannabis
US20240050450A1 (en) * 2020-10-16 2024-02-15 Michael Ogburn Inhalable Cannabinoid Formulations
KR20240093906A (ko) * 2021-10-27 2024-06-24 맨카인드 코포레이션 폐고혈압을 치료하기 위한 방법 및 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009527583A (ja) * 2006-02-22 2009-07-30 マンカインド コーポレイション ジケトピペラジン及び活性薬剤を含有する微粒子の製剤特性の改善方法
JP2019504684A (ja) * 2016-01-29 2019-02-21 マンカインド コーポレイション 乾燥粉末吸入器

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60017152D1 (de) * 1999-08-25 2005-02-03 Advanced Inhalation Res Inc Grosse poröse partikel erhältlich durch sprühtrocknung und geeignet zur pulmonalen anwendung
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
KR101644250B1 (ko) * 2004-08-23 2016-07-29 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
ES2929343T3 (es) * 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
PT3470057T (pt) * 2010-09-29 2021-12-03 Pulmatrix Operating Co Inc Pós secos catiónicos compreendendo sais de magnésio
PE20181295A1 (es) * 2015-09-01 2018-08-07 First Wave Bio Inc Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009527583A (ja) * 2006-02-22 2009-07-30 マンカインド コーポレイション ジケトピペラジン及び活性薬剤を含有する微粒子の製剤特性の改善方法
JP2019504684A (ja) * 2016-01-29 2019-02-21 マンカインド コーポレイション 乾燥粉末吸入器

Also Published As

Publication number Publication date
EP3941438A4 (en) 2022-09-21
US20220241271A1 (en) 2022-08-04
CA3133804A1 (en) 2020-10-01
JP2025061049A (ja) 2025-04-10
MX2021011491A (es) 2022-01-18
WO2020198051A1 (en) 2020-10-01
EP3941438A1 (en) 2022-01-26
MX2025008306A (es) 2025-08-01

Similar Documents

Publication Publication Date Title
AU2022224822B2 (en) Dry powder inhaler
JP2025061049A (ja) 吸入可能な乾燥粉末
US20250228779A1 (en) Method and composition for treating pulmonary fibrosis
US20240180897A1 (en) Methods and compositions for treating pulmonary hypertension
HK40111085A (zh) 用於治疗肺高压的方法和组合物
HK40077429A (en) Dry powder inhaler
JP2025514305A (ja) 肺疾患を処置するための方法および組成物
HK40096956A (zh) 治疗肺纤维化的方法和组合物
HK1258955B (en) Dry powder inhaler

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230316

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240325

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240523

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250106